創勝集團(06628.HK)發表TST001三聯療法治療胃癌研究數據
創勝集團-B(06628.HK)表示,旗下CLDN18.2靶向抗體藥物Osemitamab(TST001)聯合納武利尤單抗和
CAPOX作為晚期胃或胃食管結合部腺癌(TranStar102)一線治療,正在進行的二期臨床試驗G隊列更新研究數據,在所有82例入組患者中,經過22.6個月的中位隨訪觀察,中位總生存期(mOS)為20.4個月。
公司全球臨床開發執行副總裁戚川表示,最新G隊列研究數據顯示,無論PD-L1表達水平如何,與現有標準療法或新興療法的歷史數據相比,Osemitamab(TST001)聯合免疫檢查點抑制劑及化療能為患者帶來顯著的總生存期和無進展生存期獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.